TransUnion
TRU
$64.44
-6.50%
TransUnion is one of the three dominant credit bureaus in the United States, providing consumer credit information, fraud detection, marketing, and analytical services globally across over 30 countries. The company operates as an essential data infrastructure player within the financial services ecosystem, with a distinct competitive identity as a trusted provider of risk and marketing solutions. The current investor narrative is shaped by its strategic expansion in international markets, evidenced by the recent acquisition of majority control in Mexico's Buró de Crédito, and ongoing debates around its ability to navigate economic cycles that impact credit demand and its growth trajectory relative to peers.…
TRU
TransUnion
$64.44
Related headlines
Investment Opinion: Should I buy TRU Today?
Rating & Thesis: Hold. TRU presents a classic 'value vs. momentum' conflict where attractive forward valuation and strong cash flow are counterbalanced by a severe technical downtrend and cyclical headwinds, warranting a neutral stance until the earnings recovery path becomes clearer.
Supporting Evidence: The primary valuation metric, the forward P/E of 11.85x, is compelling for a company with 12.98% YoY revenue growth and an 18.74% TTM operating margin. The company generates robust TTM free cash flow of $661.6M, supporting a healthy current ratio of 1.75. However, the stock trades just 2.5% above its 52-week low, with a 1-year relative strength of -46.33% against the S&P 500, indicating extreme negative momentum that overshadows fundamentals.
Risks & Conditions: The two biggest risks are a failure to achieve the forward EPS of $7.77, invalidating the valuation thesis, and a breakdown below the $64.51 support level triggering further technical selling. This Hold would upgrade to a Buy if the stock establishes a higher low above $70 with improving volume, confirming a trend reversal, or if QoQ revenue growth re-accelerates above 5%. It would downgrade to a Sell if the 52-week low is breached on high volume or if forward EPS estimates are revised downward by more than 10%. Relative to its own depressed price history and the implied earnings recovery, the stock appears fairly valued to slightly undervalued, but the price action suggests the market disagrees.
Sign up to view all
TRU 12-Month Price Forecast
The investment thesis for TRU hinges on a bet that its fundamentals (cash flow, margins, oligopoly position) will ultimately outweigh terrible technicals and cyclical fears. The forward valuation is undemanding, but the stock is a 'show me' story that requires proof of the earnings recovery. The base case of range-bound consolidation is most likely, as the market awaits clearer economic signals. The stance would upgrade to bullish on a confirmed technical reversal above $80 with strong volume, or downgrade to bearish on a decisive break below $64.51 with no fundamental catalyst for a quick recovery.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransUnion's 12-month outlook, with a consensus price target around $83.77 and implied upside of +30.0% versus the current price.
Average Target
$83.77
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$52 - $84
Analyst target range
Analyst coverage appears limited with only 6 analysts providing estimates, and specific consensus recommendation and target price data are not available in the provided dataset, indicating potentially insufficient public coverage for a clear consensus. The available institutional ratings show a mix of bullish and neutral stances, with firms like Morgan Stanley (Overweight), Stifel (Buy), and Needham (Buy) maintaining positive ratings, while Goldman Sachs and Barclays are Neutral or Equal Weight, signaling cautious optimism amid uncertainty. The lack of a defined target price range and the small analyst count suggest this stock may have lower institutional visibility, which can contribute to higher volatility and less efficient price discovery compared to more widely covered peers.
Bulls vs Bears: TRU Investment Factors
The evidence currently tilts bearish due to the stock's severe technical breakdown, high volatility, and cyclical risks overshadowing its solid fundamentals. The bullish case rests on a compelling forward valuation and strong cash generation, but these are contingent on a successful earnings recovery. The single most important tension in the investment debate is whether the forward P/E of 11.85x represents a genuine value opportunity or a value trap, predicated on the company's ability to deliver on the implied $7.77 EPS estimate amidst a challenging macroeconomic backdrop for credit.
Bullish
- Strong Forward P/E of 11.85x: The forward P/E of 11.85x, based on an estimated EPS of $7.77, is a significant discount to the trailing P/E of 36.60x and suggests the market is pricing in a substantial earnings recovery. This valuation appears reasonable for a company with a dominant market position and a 12.98% YoY revenue growth rate in Q4 2025.
- Robust Free Cash Flow Generation: The company generates strong cash flow, with TTM free cash flow of $661.6 million, providing ample internal funding for growth and shareholder returns. This financial flexibility is a key strength, supporting strategic acquisitions like the recent majority stake in Mexico's Buró de Crédito.
- Improving Profitability Margins: Net margin expanded to 8.64% in Q4 2025 from 6.39% a year ago, while the TTM operating margin stands at a healthy 18.74%. This demonstrates the company's pricing power and operational leverage, with gross margins consistently near 59%.
- Essential Infrastructure with Growth: As one of three dominant U.S. credit bureaus, TransUnion operates essential data infrastructure. Its strategic international expansion, evidenced by the Mexico acquisition, provides a path for growth beyond the mature U.S. market, which still delivered $918.9 million in Q4 revenue.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 23.47% over one year and 21.88% over six months, severely underperforming the S&P 500. Trading at $66.13, it is just 2.5% above its 52-week low of $64.51, indicating persistent negative momentum and lack of buyer conviction.
- High Volatility and Market Beta: With a beta of 1.55, TRU is 55% more volatile than the broader market. This amplifies downside risk during market sell-offs and suggests the stock is highly sensitive to macroeconomic fears and interest rate changes that impact credit cycles.
- Elevated Trailing P/E Ratio: The trailing P/E of 36.60x is elevated, even if it reflects depressed earnings. This high multiple leaves the stock vulnerable to valuation compression if the expected earnings recovery, implied by the forward P/E of 11.85x, is delayed or fails to materialize.
- Revenue Concentration and Cyclicality: Approximately 78% of Q4 revenue came from the U.S. Markets segment, creating concentration risk. As a credit bureau, demand for its services is cyclical and tied to consumer credit health, making it susceptible to an economic downturn.
TRU Technical Analysis
The stock is entrenched in a pronounced downtrend, with a 1-year price change of -23.47% and a 6-month decline of -21.88%, significantly underperforming the S&P 500's 22.86% gain over the same period. Currently trading at $66.13, the price sits just 2.5% above its 52-week low of $64.51, positioning it near the bottom of its annual range, which suggests either a deep value opportunity or a continuation of negative momentum if support fails. Recent momentum shows a modest 1-month decline of -0.66% and a 3-month drop of -5.46%, indicating a deceleration in the selling pressure compared to the longer-term trend, but this does not yet constitute a reversal signal. The stock exhibits high volatility with a beta of 1.55, meaning it is 55% more volatile than the broader market, which amplifies both downside risk and potential upside during a recovery. Key technical levels are clearly defined, with immediate support at the 52-week low of $64.51 and resistance far above near the 52-week high of $99.39; a breakdown below $64.51 could trigger further capitulation, while a sustained move above the recent high near $87.71 would be necessary to signal a trend change.
Beta
1.55
1.55x market volatility
Max Drawdown
-35.0%
Largest decline past year
52-Week Range
$64-$99
Price range past year
Annual Return
-24.1%
Cumulative gain past year
| Period | TRU Return | S&P 500 |
|---|---|---|
| 1m | -6.1% | +0.3% |
| 3m | -10.1% | +12.3% |
| 6m | -26.0% | +8.9% |
| 1y | -24.1% | +24.0% |
| ytd | -22.7% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TRU Fundamental Analysis
Revenue growth remains positive but has shown volatility, with Q4 2025 revenue of $1.17 billion representing a 12.98% year-over-year increase, though this follows a sequential decline from Q3's $1.17 billion. Segment data reveals the U.S. Markets segment, contributing $918.9 million, is the primary growth driver, while the International segment at $255.8 million offers diversification but smaller scale. The company is profitable, reporting Q4 net income of $101.2 million, translating to a net margin of 8.64%, which has improved from 6.39% in the year-ago quarter, indicating margin expansion. Gross margin for the quarter was a healthy 59.35%, and the trailing twelve-month operating margin stands at 18.74%, reflecting the company's strong pricing power and scalable data platform. Balance sheet health is moderate, with a debt-to-equity ratio of 1.16, indicating leverage but within manageable levels, and a current ratio of 1.75 suggests sufficient short-term liquidity. The company generates robust cash flow, with trailing twelve-month free cash flow of $661.6 million, providing ample internal funding for growth initiatives and shareholder returns, as evidenced by consistent stock repurchases.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$661600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TRU Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 36.60x, while the forward P/E is significantly lower at 11.85x, indicating the market expects a substantial earnings recovery, with forward EPS estimates averaging $7.77. Compared to sector averages, the trailing P/E of 36.60x is likely at a premium, though specific industry average data is not provided; the forward multiple of 11.85x appears more reasonable if earnings estimates are achieved. Historically, the stock's own trailing P/E has ranged widely, from a low near 5.59x in late 2021 to highs above 100x; the current 36.60x is above the median of its recent history, suggesting the market is still pricing in a recovery but remains cautious relative to peak optimism.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -11x~103x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TransUnion's primary financial risk is its cyclical revenue model, with ~78% of Q4 sales from U.S. Markets, making it vulnerable to a downturn in consumer credit demand. While the debt-to-equity ratio of 1.16 is manageable, the elevated trailing P/E of 36.60x creates valuation risk if the anticipated earnings rebound (to a forward P/E of 11.85x) is delayed. Furthermore, quarterly revenue has shown volatility, with Q4 2025 at $1.17B following a sequential dip from Q3, indicating potential growth inconsistency.
Market & Competitive Risks: The stock's high beta of 1.55 signifies amplified sensitivity to broader market swings and sector rotation away from cyclical names. Trading near its 52-week low after a 23.47% annual decline, it faces significant momentum and sentiment headwinds. Competitively, while its oligopoly position is strong, news of AI-driven lenders like Upstart developing their own tools highlights a long-term disruptive threat to traditional credit assessment models, though the near-term impact is limited.
Worst-Case Scenario: The worst-case scenario involves a U.S. recession leading to a sharp contraction in credit inquiries and loan originations, causing TRU to miss forward EPS estimates of $7.77. This would trigger multiple compression from the current forward P/E, coupled with continued technical selling pressure. A realistic downside could see the stock re-test and break its 52-week low of $64.51, potentially falling towards the $55-$60 range, representing a further 10-20% decline from the current price of $66.13, exacerbated by its high volatility.
FAQ
The key risks are, in order of severity: 1) Macroeconomic/Cyclical Risk: A recession would directly reduce credit demand, impacting ~78% of revenue from U.S. Markets, as evidenced by the stock's high beta of 1.55. 2) Valuation Risk: The high trailing P/E of 36.60x is vulnerable to compression if forward EPS estimates of $7.77 are not met. 3) Technical/Momentum Risk: The stock is in a severe downtrend, trading just 2.5% above its 52-week low, which can become a self-fulfilling prophecy. 4) Competitive Risk: Long-term disruption from AI-driven lending platforms, though the near-term threat to its oligopoly is limited.
The 12-month forecast is a base-case target range of $70 to $80 (55% probability), predicated on the company meeting lower-end EPS estimates around $7.32 and the stock consolidating after its steep decline. The bull case (25% probability) targets $85 to $99 if EPS meets or exceeds $7.77 and credit markets remain strong. The bear case (20% probability) sees a drop to $55 to $65 if a recession hits and earnings disappoint. The most likely scenario is base-case consolidation, as the market requires proof that the forward earnings estimates are achievable before re-rating the stock higher.
TRU's valuation is bifurcated. Based on trailing earnings (P/E of 36.60x), it appears expensive. However, the forward P/E of 11.85x, based on analyst EPS estimates of $7.77, suggests it is undervalued if those estimates are achieved. This discount implies the market is skeptical about the earnings recovery. Compared to its own 52-week high near $99, the stock is deeply discounted, but relative to its low of $64.51, it is near the bottom of its range. The valuation is fair to slightly undervalued based on forward estimates, but richly valued based on current earnings.
TRU is a high-risk, potentially high-reward stock that is not a good buy for all investors. For a value investor with a multi-year horizon, the forward P/E of 11.85x and strong free cash flow yield of ~4.0% may be attractive. However, given its severe downtrend (down 23.47% in a year), high beta of 1.55, and cyclical exposure, it is a poor choice for short-term traders or risk-averse investors. It could be a good buy on a further dip towards its 52-week low for those believing in an earnings recovery, but it requires a high risk tolerance.
TRU is unsuitable for short-term investment due to its high volatility (beta 1.55) and entrenched downtrend, which could lead to significant losses. It is better suited for a long-term (3+ year) investment horizon, allowing time for its fundamental strengths—strong cash flow, essential market position, and international growth—to overcome cyclical pressures and for the forward earnings recovery to materialize. The lack of a meaningful dividend (yield 0.54%) further supports a growth-oriented, long-term holding strategy. A minimum holding period of 18-24 months is suggested to weather potential economic cycles.